Article Versions Notes

Müller JA, Buchberger J, Schmidt-Riese E, Pitzschel C, Möller M, Schütte W, Medenwald D, Vordermark D. Real-World Outcomes of Chemoradiotherapy in Patients with Stage II/III Non-Small-Cell Lung Cancer in the Durvalumab Era: An Observational Study. Cancers. 2025; 17(15):2498. https://doi.org/10.3390/cancers17152498

Müller, Jörg Andreas, Jonas Buchberger, Elias Schmidt-Riese, Clara Pitzschel, Miriam Möller, Wolfgang Schütte, Daniel Medenwald, and Dirk Vordermark. 2025. "Real-World Outcomes of Chemoradiotherapy in Patients with Stage II/III Non-Small-Cell Lung Cancer in the Durvalumab Era: An Observational Study" Cancers 17, no. 15: 2498. https://doi.org/10.3390/cancers17152498

Müller, J. A., Buchberger, J., Schmidt-Riese, E., Pitzschel, C., Möller, M., Schütte, W., Medenwald, D., & Vordermark, D. (2025). Real-World Outcomes of Chemoradiotherapy in Patients with Stage II/III Non-Small-Cell Lung Cancer in the Durvalumab Era: An Observational Study. Cancers, 17(15), 2498. https://doi.org/10.3390/cancers17152498